Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32255
Title: First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.
Austin Authors: Reck, Martin;Ciuleanu, Tudor-Eliade;Cobo, Manuel;Schenker, Michael;Zurawski, Bogdan;Menezes, Juliana;Richardet, Eduardo;Bennouna, Jaafar;Felip, Enriqueta;Juan-Vidal, Oscar;Alexandru, Aurelia;Cheng, Ying;Sakai, Hiroshi;Paz-Ares, Luis;Lu, Shun;John, Thomas ;Sun, Xiaowu;Moisei, Aniela;Taylor, Fiona;Lawrance, Rachael;Zhang, Xiaoqing;Sylvester, Judi;Yuan, Yong;Blum, Steven I;Penrod, John R;Carbone, David P
Affiliation: Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungClinic, Grosshansdorf, Germany.
Department of Oncology, Institutul Oncologic Prof. Dr. Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania.
Department of Medical Oncology, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain.
Department of Oncology, SF Nectarie Oncology Center, Craiova, Romania.
Department of Clinical Oncology, Ambulatorium Chemioterapii, Bydgoszcz, Poland.
Department of Oncology, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil.
Department of Clinical Oncology, Instituto Oncológico de Córdoba, Córdoba, Argentina.
Department of Thoracic Oncology, University Hospital of Nantes and INSERM, CRCINA, Nantes, France.
Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Department of Medical Oncology, Hospital Universitario La Fe, Valencia, Spain.
Department of Oncology, Institute of Oncology Prof Dr Alexandru Trestioreanu Bucha, Bucharest, Romania.
Department of Medical Oncology, Jilin Cancer Hospital, Changchun, China.
Department of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan.
Department of Medical Oncology, Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Clinical Research Unit, Universidad Complutense & CiberOnc, Madrid, Spain.
Department of Medical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Medical Oncology
Adelphi Values, Boston, MA, USA.
Adelphi Values, Adelphi Mill, Grimshaw Ln, Bollington, Cheshire, UK.
Bristol Myers Squibb, Princeton, NJ, USA.
Department of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Issue Date: 28-Jan-2023
Date: 2023
Publication information: European Journal of Cancer 2023; 183
Abstract: In CheckMate 9LA (NCT03215706), first-line nivolumab plus ipilimumab with chemotherapy (2 cycles) significantly improved overall survival versus chemotherapy (4 cycles) in patients with metastatic non-small cell lung cancer and no known sensitising epidermal growth factor receptor/anaplastic lymphoma kinase alterations. We present exploratory patient-reported outcomes (PROs; minimum follow-up, 2 years).
URI: https://ahro.austin.org.au/austinjspui/handle/1/32255
DOI: 10.1016/j.ejca.2023.01.015
ORCID: 
Journal: European Journal of Cancer
Start page: 174
End page: 187
PubMed URL: 36871487
ISSN: 1879-0852
Type: Journal Article
Subjects: CTLA-4 inhibitor
Health-related quality of life
Immune-checkpoint inhibitors
Immunotherapy
Non-small cell lung cancer
Patient-reported outcomes
Programmed death (PD)-1 inhibitor
Symptom burden
Appears in Collections:Journal articles

Show full item record

Page view(s)

40
checked on May 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.